Category: Business

Nvidia (NVDA) continues to dominate the AI chip market, with its graphics processing units (GPUs) serving as the preferred hardware for training and running the majority of AI applications. However, because GPUs are designed for general-purpose computing, a significant portion of their computing capacity can go underutilized when handling highly repetitive and specialized AI workloads....

The cryptocurrency market has a well-established history of moving through four-year boom-and-bust cycles, making 2027 a potentially critical year for investors. If 2026 develops into a downturn or “bust” year, the conditions for a new crypto bull market beginning in 2027 could become increasingly favorable. According to analysts at Eidellux, the key question is where...

Super Micro Computer (SMCI) stock is surging today, up as much as 17.71% intraday and still showing a 15.3% gain as of 1:10 p.m. ET  a striking move against a broader market that’s actually moving in the opposite direction, with the S&P 500 down 0.4% and the Nasdaq Composite off 1.2% on the same day. ...

Bristol Myers Squibb (BMY) shares have gone essentially nowhere for the past several years, and the reason comes down to two words that strike fear into pharmaceutical investors: “patent cliff.”  Just two drugs  Eliquis and Opdivo  generated more than $24.4 billion in sales last year, roughly half of the company’s total revenue. U.S. market exclusivity...

Asking whether a stock can double in value is a valuable exercise because it requires investors to evaluate both the company’s long-term growth potential and its current valuation. A stock that scores well on both fronts often deserves closer attention. Microsoft (MSFT) is increasingly emerging as one of those candidates. While the company remains one...

The troubled private-credit industry was under further pressure after a report that JPMorgan Chase was tightening its lending criteria while a $33 billion fund was reported to have seen heavy withdrawals.

Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both diabetes and weight loss are under threat.

Hims & Hers shares jumped nearly 50% in premarket trade on Monday after a report it has ended a dispute with Novo Nordisk by striking a partnership with the Danish drug giant.